Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platforms to potential new drug candidates is therefore very uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; (vi) if Nektar is unable to establish and maintain collaboration partnerships on attractive commercial terms (such as for NKTR-102), our business, results of operations and financial condition could suffer; and (vii) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the SEC on July 28, 2010, the Current Report on Form 8-K filed with the SEC today, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 to be filed with the SEC on or about November 4, 2010.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics(650) 631-4954Susan Noonan/SA Noonan Communications, LLC(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners(650) 575-1509 Michelle Corral/BCC Partners(415) 794-866
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)...   Hospira, Inc. (NYSE: HSP ... infusion technologies, today announced that the company will present ... Wednesday, Jan. 14, 2015, in San Francisco.  ... 10:30 a.m. Pacific time on Wednesday, Jan. 14, 2015.  ... a live audiocast accessible via the Investor Relations section ...
(Date:12/19/2014)... 19, 2014 In today,s rapidly changing, ... communication tools are essential for survival. The world ... consumers, desires, preferences, and unmet needs are evolving ... groups across all industries are continually searching for ... the adoption of new market research techniques like ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... of Sustainable, Organic Livestock and ... ... Neptune Industries,Inc. (OTC Bulletin Board: NPDI), a next generation aquaculture technology,company ... production, and related,natural and organic food products, announced today that Phase ...
... Open Label Trial Published in Online Edition ... of ... reduced hemolysis and improved fatigue, overall,quality of life and anemia in ... nocturnal hemoglobinuria (PNH), according,to an analysis of the Phase III SHEPHERD ...
Cached Medicine Technology:Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 2Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 3Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 4Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 2Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 3Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 4Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 5Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 6Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 7
(Date:12/22/2014)... NAPW honors Cheryl ... the Year. She is recognized with this prestigious distinction ... networking organization of professional women in the country, spanning ... Professional Women is a vibrant networking community with over ... Kreider is passionate and committed to best practices that ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/22/2014)... 2014 Parker & Sons, Inc. a ... Arizona home contracting services reports a record number of ... services in 2014. As a company that has served ... Parker and Sons is a business that is focused ... side-by-side with other top quality companies in Arizona that ...
(Date:12/21/2014)... BambooFlooringChina.com, a famous bamboo lumber supplier, has announced ... launched a bamboo flooring promotion with great discounts, up ... 2015. , According to the CEO of the business, ... today; it has a highly distinctive grain with a ... bamboo is made by a unique manufacturing process which ...
(Date:12/21/2014)... 2014 BellasDress.com offers a wide range ... Today, it announces its BellasDress Christmas Sale , ... online store. , BellasDress is a famous online supplier ... fans through a series of promotions. The dress experts ... , “We are proud of offering high quality ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... and sanitation severely limited in Lebanon due to Israeli ... for a coordinated, regional response to the crisis. // ... patients with chronic conditions is a major concern," according ... Israel retaliated to the cross border Hizbollah attacks on ...
... today said it will issue 20 lakh equity shares to ... // ,The board of directors has approved the ... a price of Rs 100 on a preferential basis to ... Stock Exchange., ,The board also approved the allotment of ...
... Health experts have warned that many of the youths ... may undergo premature ageing.// ,The experts explained ... toll on the health of the youth. Dr Lim ... disorders unit, Singapore General Hospital, said, "Heavy food during ...
... avert about 5,7-million HIV infections by 2026.// ... of Science Medicine, stated that male circumcision could avert ... over the next decade. ,According to the ... 2,7-million deaths by 2026. Because circumcision reduces male vulnerability ...
... be vigilant about meningococcal disease after a two-year-old boy died ... on Saturday with fever-like symptoms, but was sent to the ... emergency department. Queensland Health spokesman Dr Jeffrey Hanna said that ... shifted to the hospital. ,"The question for us ...
... ablation and radiation therapy, when used to treat patients ... cancer, increases chances of survival//, say researchers ... study looking at patients over seven years, the median ... after radiation alone to 42 months when thermal ablation ...
Cached Medicine News:Health News:Circumcision to Avert HIV Infection 2Health News:Combination Therapy to the Rescue off Lung Cancer Patients 2Health News:Combination Therapy to the Rescue off Lung Cancer Patients 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: